- Author:
Gang DAI
1
Author Information
- Publication Type:Journal Article
- Keywords: Mergers and acquisitions; Pharmaceutical company; Trend analysis
- From: Chinese Pharmaceutical Journal 2018;53(23):2065-2068
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To summarize and analyze the representative cases of large-scale mergers and acquisitions in the global pharmaceutical industry in order to form a reference for domestic pharmaceutical companies to use for reference in the scientific development of M&A strategy and transformation.METHODS: By reviewing relevant literature and information at home and abroad, and combining specific case studies, the status and trends of mergers and acquisitions in the global pharmaceutical industry in recent years were analyzed.RESULTS AND CONCLUSION: In recent years, the number of mergers and acquisitions cases in the global pharmaceutical industry is numerous, and the amount involved in mergers and acquisitions is relatively large. From 2013 to 2015, the number and amount of M&A transactions in global pharmaceutical companies are on the rise. In 2015, it became the year of mergers and acquisitions in the pharmaceutical industry. This shows that some pharmaceutical companies are facing patent expiration of their major profitable products. The new drug development process has encountered many difficulties and faced pressure to expand product lines, expand market share, and increase core competitiveness, further contributing to corporate mergers and reorganizations. From 2016 to 2017, the number and amount of M&A transactions declined, and M&A activities were different from the target audience, M&A motives and methods, and the companies were more cautious. This article discusses mergers and acquisitions trends in the global pharmaceutical industry, major businesses involved in mergers and acquisitions, and active pharmaceutical companies and their characteristics, and analyzes the development trends of global pharmaceutical industry mergers and acquisitions for domestic pharmaceutical companies and industry managers to reference.